Get the Stockscreener App
10.36
0.00%
0.00
After Hours:
10.34
-0.02
-0.19%
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Viatris Inc stock is traded at $10.36, with a volume of 12.03M.
It is up +0.00% in the last 24 hours and up +4.65% over the past month.
Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. The remaining 60% of sales are derived from its portfolio of legacy products, which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.
See More
Previous Close:
$10.36
Open:
$10.31
24h Volume:
12.03M
Relative Volume:
1.29
Market Cap:
$12.08B
Revenue:
$14.33B
Net Income/Loss:
$-3.79B
P/E Ratio:
-3.2681
EPS:
-3.17
Net Cash Flow:
$1.84B
1W Performance:
+0.10%
1M Performance:
+4.65%
6M Performance:
+23.04%
1Y Performance:
-10.69%
1-Day Range:
$10.24
$10.43
1-Week Range:
$10.18
$10.46
52-Week Range:
$6.85
$13.55
Viatris Inc Stock (VTRS) Company Profile
Name
Viatris Inc
Sector
Phone
(724) 514-1465
Address
1000 MYLAN BOULEVARD, CANONSBURG
Compare VTRS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VTRS
Viatris Inc
|
10.36 | 11.96B | 14.33B | -3.79B | 1.84B | -3.17 |
|
ZTS
Zoetis Inc
|
144.09 | 63.86B | 9.39B | 2.62B | 2.22B | 5.8121 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.44 | 41.80B | 29.96B | 957.25M | 4.77B | 0.2956 |
|
HLN
Haleon Plc Adr
|
9.27 | 40.88B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
20.48 | 22.98B | 16.70B | -157.13M | 1.19B | -0.1446 |
|
UTHR
United Therapeutics Corp
|
445.43 | 19.53B | 3.08B | 1.24B | 1.07B | 25.61 |
Viatris Inc Stock (VTRS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-15-25 | Initiated | Truist | Buy |
| Jun-06-25 | Initiated | Goldman | Neutral |
| Jul-19-24 | Resumed | Jefferies | Buy |
| Oct-23-23 | Downgrade | BofA Securities | Neutral → Underperform |
| Jun-23-23 | Downgrade | Barclays | Equal Weight → Underweight |
| Apr-24-23 | Downgrade | Barclays | Overweight → Equal Weight |
| Feb-17-23 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Jan-27-23 | Upgrade | Jefferies | Hold → Buy |
| Nov-10-22 | Upgrade | UBS | Sell → Neutral |
| Nov-08-22 | Upgrade | Piper Sandler | Underweight → Neutral |
| Oct-21-22 | Resumed | Jefferies | Hold |
| Jun-14-22 | Initiated | UBS | Sell |
| May-10-22 | Downgrade | Piper Sandler | Neutral → Underweight |
| Mar-01-22 | Downgrade | BofA Securities | Buy → Neutral |
| Mar-01-22 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Jun-15-21 | Initiated | Citigroup | Neutral |
| Apr-07-21 | Resumed | RBC Capital Mkts | Outperform |
| Mar-08-21 | Downgrade | Goldman | Buy → Neutral |
| Mar-02-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Feb-26-21 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Jan-05-21 | Initiated | Argus | Hold |
| Dec-14-20 | Initiated | Bernstein | Mkt Perform |
View All
Viatris Inc Stock (VTRS) Latest News
Viatris Inc. stock outlook for YEARJuly 2025 Decliners & Smart Investment Allocation Insights - newser.com
What is the fair value estimate for Viatris Inc. (VIA) stock in 2025Market Volume Summary & Fast Exit/Entry Strategy Plans - newser.com
Is Viatris Inc. (VIA) stock overpriced at current multiplesJuly 2025 Analyst Calls & AI Powered Buy and Sell Recommendations - newser.com
Is now a turning point for Viatris Inc.2025 Big Picture & Daily Stock Trend Watchlist - newser.com
Can volume confirm reversal in Viatris Inc.Quarterly Profit Summary & Low Risk Entry Point Tips - newser.com
Will Viatris Inc. stock go up soonPortfolio Risk Report & Safe Swing Trade Setup Alerts - newser.com
Will Viatris Inc. stock recover faster than peersJuly 2025 News Drivers & Expert-Curated Trade Recommendations - newser.com
What does recent volatility data suggest for Viatris Inc.2025 Market Sentiment & Community Driven Trade Alerts - newser.com
Should you wait for a breakout in Viatris Inc.2025 Short Interest & Free Growth Oriented Trading Recommendations - newser.com
Will Viatris Inc. stock reach Wall Street targetsTrade Exit Summary & Community Consensus Trade Signals - newser.com
Viatris marked 25 years of advancing cardiovascular health in Vietnam - VnExpress International
What’s the recovery path for long term holders of Viatris Inc.Weekly Profit Report & Daily Growth Stock Investment Tips - newser.com
Will Viatris Inc. stock return to pre crisis levelsJuly 2025 Earnings & Verified High Yield Trade Plans - newser.com
Is Viatris Inc. stock a good choice for value investorsPortfolio Risk Summary & Technical Pattern Based Buy Signals - newser.com
Viatris (VTRS) Expected to Beat Earnings Estimates: Should You Buy? - sharewise.com
Viatris (VTRS): Assessing Valuation After New AI-Powered Bacteriophage Partnership with Locus Biosciences - Yahoo Finance
Will Viatris Inc. stock benefit from upcoming earnings reportsLong Setup & Weekly Top Gainers Alerts - newser.com
Inside a Heart Attack: How Awareness and Timely Intervention Can Make all the Difference - Viatris
Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields - Benzinga
Is Viatris (VTRS) Stock Undervalued Right Now? - sharewise.com
Transdermal Skin Patches Market Set for Booming Growth from 2025 - openPR.com
Viatris (VTRS) Backs Phage Therapy for Eye Infections Might Change The Case For Investing - simplywall.st
Mydriasis Market to Reach New Heights in Growth by 2034, DelveInsight Predicts | Viatris/Ocuphire Pharma, Eyenovia, Rayner Surgical/Omeros, Eyenovia, Taejoon Pharma - Barchart.com
Collaborating to Address Antimicrobial Resistance at Viatris - ACCESS Newswire
Viatris Inc Stock (VTRS) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.19%
3.75%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):